MELVILLE, N.Y., July 20, 2015 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BRT” or “the Company”) (OTCQB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Company has begun to evaluate encapsulation technology for potential use as a cell delivery system for the Company’s metabolic program.
Cell microencapsulation technology allows for the positioning of cells in a semi-permeable membrane and provides for a bidirectional diffusion of molecules essential for cell metabolism. In addition, the semi-permeable nature of the membrane prevents immune cells and antibodies from destroying the encapsulated cells.
BioRestorative’s ThermoStem® Program uses brown adipose (fat) derived stem cells as a platform for the development of cell-based therapy targeting metabolic disorders such as obesity and type 2 diabetes. Previously published studies by the Company demonstrate, in pre-clinical animal models, that 3D transplanted brown adipose constructs could ameliorate the symptoms of metabolic disorders.
The Company is advancing the development of its brown adipose cell therapy program by evaluating certain cell delivery encapsulation technology that would enable transplanted brown adipose cells to effectively maintain or regulate normal metabolism in humans. BRT is evaluating the next generation of brown adipose tissue constructs that will first be tested in small animal models.
“We look forward to further exploring encapsulation technology as a potential delivery system for the ThermoStem® Program. This could enable the Company to move one step closer to human trials utilizing transplanted brown adipose cells to treat metabolic syndrome,” said Mark Weinreb, CEO. “Our pre-clinical animal studies have shown great promise and we continue to identify ways to develop a successful therapy for medical issues that have reached pandemic levels worldwide.”
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
• Disc/Spine Program: Our lead cell therapy candidate, brtxDISC™ (Disc Implanted Stem Cells), is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The treatment involves collecting a patient’s own stem cells, culturing and cryopreserving the cells, and then having a physician inject brtxDISC™ into the patient’s damaged disc in an outpatient procedure. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery.
• Metabolic Program (ThermoStem®): We are developing an allogeneic cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company’s Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT: Lee Roth / David Burke The Ruth Group for BioRestorative Therapies 646-536-7012 / 7009 lroth@theruthgroup.com / dburke@theruthgroup.com
Help employers find you! Check out all the jobs and post your resume.
